Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics

Molecular and Cellular Biochemistry

Volumn 174, Issue 1-2, 1997, Pages 255-259

  Maurer, Iris ^a   Möller, Hans Jürgen ^b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Complex I; Mitochondria; Neuroleptics; Oxidative phosphorylation

Indexed keywords

CHLORPROMAZINE; CITRATE SYNTHASE; CLOZAPINE; CYTOCHROME C OXIDASE; HALOPERIDOL; NEUROLEPTIC AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RISPERIDONE; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; ZOTEPINE;

ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRAPYRAMIDAL SYSTEM; HUMAN; HUMAN TISSUE; MITOCHONDRIAL RESPIRATION; NEUROTOXICITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; HUMANS; MITOCHONDRIA; NAD(P)H DEHYDROGENASE (QUINONE); NEURONS; RATS;

EID: 0030869160     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006872911332     Document Type: Article

References (26)

1. Baron JC, Martinet JL, Cambon H et al: Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacol 99: 463-472, 1989
2. Schapira AHV: Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Mov Disord 9: 125-138, 1994
3. Parker WD, Boyson SJ, Parks JK: Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-723, 1989
4. Shoffner JM, Watts RL, Juncos JL, Torroni A, Wallace DC: Mitochondrial oxidative phosphorylation defects in Parkinson's disease. Ann Neurol 30: 332-339, 1991
5. Ramsay RR, Dadgar J, Trevor A, Singer TP: Energy-driven uptake of N-methyl-4-phenylpyridine by brain mitochondria mediates the neurotoxicity of MPTP. Life Sci 39: 581-588, 1986
6. Subramanyam B, Rollema H, Woolf T, Castagnoli N: Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166: 238-244, 1990
7. Burkhardt C, Kelly JP, Lim Y-H, Filley CM, Parker WD: Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol 33: 512-517, 1993
8. Jackson Lewis V, Przedborski S, Jiang H, Fahn S: Effect of neuroleptics on the mitochondrial electron transport chain [abstract]. Soc Neurosci Abstr 18: 1103, 1992
9. +, a metabolite of the neurotoxin MPTP. Life Sci 36: 2503-2508, 1985
10. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin reagent. J Biol Chem 193: 265-275, 1951
11. Casey DE: Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacol 99: S47-S53, 1989
12. Matsuda LA, Schmidt CJ, Hanson GR, Gibb JW: Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) on striatal tyrosine hydroxylase and tryptophan hydroxylase in rat. Neuropharmacology 25: 249-255, 1986
13. 35-chlorpromazine in brain. Arch Neurol Psychiat 75: 54-56, 1995
14. 35S-chlorpromazine in mice studied by whole body autoradiography. Arch Int Pharmacodyn 156: 34-46, 1965
15. 35S-chlorpromazine in the neuromelanin of human substantia nigra and locus coeruleus. Arch Int Pharmacodyn 200: 190-195, 1972
16. Sunderland T, Cohen BM: Blood to brain distribution of neuroleptics. Psychiatr Res 20: 299-305, 1987
17. Noda K, Suzuki A, Okui M, Noguchi H, Nishiura M, Nishiura N: Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzothiepine (zotepine) in rat, mouse, dog and man. Drug Res 29: 1595-1600, 1979
18. Burt DR, Creese I, Snyder SH: Antischizophrenic drugs: chronic treatment elevates dopamine binding in brain. Science 196: 326-328, 1977
19. Costall B, Fortune DH, Naylor RJ, Marsden CD, Pycock C: Serotoninergic involvement with neuroleptic catalepsy. Neuropharmacology 14: 859-868, 1975
20. Przedborski S, Jackson-Lewis V, Muthane U et al.: Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 34: 715-723, 1993
21. Nielsen EB, Lyon M: Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology 59: 85-89, 1978
22. Fibiger HC, Lloyd KG: Is the dopamine hypothesis of tardive dyskinesia completely wrong? Trends Neuro Sci 9: 259-260, 1986
23. Linnane AW, Marzuki S, Ozawa T, Tanaka M: Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 3: 642-645, 1989
24. Wallace DC: Mitochondrial genetics: A paradigm for ageing and degenerative diseases? Science 256: 628-632, 1992
25. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC: Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. 13 Nature Genet 2: 324-329, 1992
26. Soong NW, Hinton DR, Cortopassi G, Arnheim N: Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nature Genet 2: 318-323, 1992